Overview

A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or metastatic gastric cancer who had not received prior chemotherapy for advanced or metastatic disease.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Collaborators:

Chugai Pharmaceutical
Hoffmann-La Roche

Treatments:

Bevacizumab
Capecitabine
Cisplatin
Fluorouracil